Your Messages Inbox
Your Article Summary
See Latest ArticlesStepped-dose efavirenz reduces neuropsychiatric events
American Pharmacists Association, 08/26/09
Results from a randomized, double–blind controlled trial showed that initiating efavirenz in patients with HIV–1 infection in a stepwise dose schedule over a 2–week period reduced the incidence and intensity of neuropsychiatric adverse events without compromising virologic efficacy.
Related Articles
TREX1 Gene Variant in Neuropsychiatric Systemic Lupus Erythematosus
Annals of Rheumatic Diseases, 11/11/09
Relevance Score: 85%
Clinical implications of neuropsychiatric systemic lupus erythematosus
Advances in Psychiatric Treatment, 11/04/09
Relevance Score: 84%
Homocysteine, folate and vitamin B12 in neuropsychiatric diseases: review and treatment recommendations
Expert Review of Neurotherapeutics, 10/08/09
Relevance Score: 84%
Neuropsychiatric Systemic Lupus Erythematosus Presenting as Bipolar I Disorder With Catatonic Features
Psychosomatics, 10/29/09
Relevance Score: 83%
Retinal Response to Light in Young Nonaffected Offspring at High Genetic Risk of Neuropsychiatric Brain Disorders
Biological Psychiatry, 10/23/09
Relevance Score: 83%
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
Sanofi Pasteur expands study of vaccine against Clostridium difficile into the U.S.
Sanofi-aventis, 12/16/09
A Clinical Review of Echinocandins in Pediatric Patients
Annals of Pharmacotherapy, 12/16/09
Second Pivotal Phase III Study of Gileads Darusentan for Resistant Hypertension Misses Primary Endpoints
Gilead, 12/15/09
Article Search
Sponsor